This article is more than 5 years old. Information may no longer be current.

EyeGate posts quarterly loss

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

EyeGate Pharmaceuticals reported a net loss of $2.78 million in the second quarter of 2018, compared to a net loss of $3.327 million in the second quarter of 2018.

Research and development costs decreased from $2.262 million in 2017’s second quarter to $1.838 million in 2018, due to decreases in clinical activity for the company’s post cataract surgery inflammation and pain treatment EGP-437, according to a company press release.

General and administrative expenses were $1.203 million for the quarter compared to 2017’s second quarter expenses of $1.213 million.

EyeGate had cash and cash equivalents of $12.605 million as of June 30, 2018.